Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice

European Journal of Pharmacology

Volumn 324, Issue 2-3, 1997, Pages 135-140

  Noda, Yukihiro ^a   Mamiya, Takayoshi ^a   Furukawa, Hiroshi ^b   Nabeshima, Toshitaka ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MEIJO UNIVERSITY   (Japan)

Author keywords

5 HT (5 hydroxytryptamine, seotonin); Antidepressant; Depression; Forced swimming test; Mouse; Phencyclidine; Schizophrenia, negative symptom

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; IMIPRAMINE; MIANSERIN; PHENCYCLIDINE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; FORCED SWIMMING TEST; MALE; MOUSE; NEGATIVE SYNDROME; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DESIPRAMINE; HALLUCINOGENS; HYDROXYINDOLEACETIC ACID; MALE; MIANSERIN; MICE; PHENCYCLIDINE; PREFRONTAL CORTEX; SCHIZOPHRENIA; SEROTONIN; STRESS; SWIMMING;

EID: 0031003482     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)00067-8     Document Type: Article

References (36)

1. Andreasen, N.C., 1990, Methods for assessing positive and negative symptoms, Mod. Probl. Pharmacopsychiatry 24, 73.
2. Baldessarini, R.J. and R.L. Willmuth, 1968, Psychotic reactions during amitriptyline therapy, Can. Psychoatr. Assoc. J. 13, 571.
3. Barnes, T.R.E., D.A. Curson, P.F. Liddle and M. Patel, 1989, The nature and prevalence of depression in chronic schizophrenic in-patients, Br. J. Psychiatry 154, 486.
4. Blier, P., C. De Montigny and Y. Chaput, 1990, A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence, J. Clin. Psychiatry 51 (Suppl. 4), 14.
5. Borsini, F., 1995, Role of the serotonergic system in the forced swimming test, Neurosci. Biobehav. Rev. 19, 377.
6. Contreras, P.C., K.C. Rice, A.E. Jacobson and T.L. O'Donohue, 1986, Stereotyped behavior correlates better than ataxia with phencyclidine-receptor interactions, Eur. J. Pharmacol. 121, 9.
7. Danysz, W., A. Plaznik, W. Kostowski, E. Malatynska, T.V.C. Jarbe, A.J. Hiltunen and T. Archer, 1988, Comparison of desipramine, amitriptyline, zimelidine and alaproclate in six animal models used to investigate antidepressant drugs, Pharmacol. Toxicol. 62, 42.
8. Dickerson, F.B., N.B. Ringel and J.J. Boronow, 1991, Neuropsychological deficits in chronic schizophrenics. Relationship with symptoms and behavior, J. Nerv. Ment. Dis. 179, 744.
9. Duinkerke, S.J., P.A. Botter, A.A.I. Jansen, P.A.M. Van Donegen, A.J. Van Haaften, A.J. Boom, J.H.M. Van Laarhoven and H.L.S.M. Busard, 1993, Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia: a placebo-controlled double-blind trial, Br. J. Psychiatry 163, 451.
10. Elliott, H., K. McLean, D. Sumner and J. Reid, 1983, Absence of an effect of mianserin on the actions of clonidine or methyldopa in hypertensive patients, Eur. J. Pharmacol. 24, 15.
11. Fenton, W.S. and T.H. McGlashan, 1992, Testing system for assessment of negative symptoms in schizophrenia, Arch. Gen. Psychiatry 49, 179.
12. Hand, T., G. Marek and L. Seiden, 1991, Comparison of the effects of mianserin and its enantiomers and metabolites on a behavioral screen for antidepressant activity, Psychopharmacology 105, 453.
13. Hiramatsu, M., A.K. Cho and T. Nabeshima, 1989, Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine, Eur. J. Pharmacol. 166, 359.
14. Hurlbut, K.M., 1991, Drug-induced psychoses, Emerg. Med. Clin. North. Am. 9, 31.
15. Javitt, D.C., 1987, Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia, Hillside J. Clin. Psychiatry 9, 12.
16. Javitt, D.C. and S.R. Zukin, 1991, Recent advances in the phencyclidine model of schizophrenia, Am. J. Psychiatry 148, 1301.
17. 3H-TCP binding to rat cortical membranes: effects of divalent cations and glycine, in: Proceedings of the Second U.S.-French Sponsored International Seminar: Sigma and Phencyclidine-like Compounds as Molecular Probes in Biology, eds. E.F. Domino and J.M. Kamenka (NPP Books, New York/Ann Arbor, MI) p. 259.
18. Kukla, F. and R. Gold, 1991, Negative schizophrenic symptoms and their detection, Fortschr. Neurol. Psychiatr. 59, 60.
19. Lindenmayer, J.P., 1995, New pharmacotherapeutic modalities for negative symptoms in psychosis, Acta Psychiatr. Scand. 91, 15.
20. Löscher, W., R. Annies and D. Honack, 1991, The N-methyl-D-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats, Neurosci. Lett. 128, 191
21. Maj, J., Z. Rogóź, G. Skuza and H. Sowińska, 1992, Effects of MK-801 and antidepressant drugs in the forced swimming test in rats, Eur. Neuropsychopharmacol. 2, 37.
22. Meltzer, H.Y., 1989, Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia, Psychopharmacology 99, S18.
23. Mizuki, Y., N. Kajimura, S. Kai, M. Suetsugi, I. Ushijima and M. Yamada, 1992, Effects of mianserin in chronic schizophrenia, Prog. Neuro-Psychopharmacol. Biol. Psychiatry 16, 517.
24. Nitta, A., Y. Furukawa, K. Hayashi, M. Hiramatsu, T. Kameyama and T. Nabeshima, 1992, Denervation of dopaminergic neurons with 6-hydroxydopamine increases nerve growth factor content in rat brain, Neurosci. Lett. 144, 152.
25. Nixon, M.K., M. Hascoet, M. Bourin and M.C. Colombel, 1994, Additive effects of lithium and antidepressants in the forced swimming test: further evidence for involvement of the serotoninergic system, Psychopharmacology 115, 59.
26. Noda, Y., K. Yamada, H. Furukawa and T. Nabeshima, 1995, Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia, Br. J. Pharmacol. 116, 2531.
27. Peralta, V., J. De-Leon and M.J. Cuesta, 1992, Are there more than two syndromes in schizophrenia? A critique of the positive-negative dichotomy, Br. J. Psychiatry 161, 335.
28. Porsolt, R.D., A. Bertin and M. Jalfre, 1977a, Behavioural despair in mice: a primary screening test for antidepressants, Arch. Int. Pharmacodyn. 229, 327.
29. Porsolt, R.D., M. Le Pichon and M. Jalfre, 1977b, Depression: a new animal model sensitive to antidepressant treatments, Nature 266, 730.
30. Porsolt, R.D., G. Anton, N. Blavet and M. Jalfre, 1978, Behavioural despair in rats: a new model sensitive to antidepressant treatments, Eur. J. Pharmacol. 47, 379.
31. Sanger, D.J. and D. Joly, 1991, Effects of NMDA receptor antagonists and sigma ligands on the acquisition of conditioned fear in mice, Psychopharmacology 104, 27.
32. Siris, S.G., D.P. Van Kammen and J.P. Docherty, 1978, Use of antidepressant drugs in schizophrenia, Arch. Gen. Psychiatry 35, 1368.
33. Siris, S.G., P.C. Bermanzohn, A. Gonzalez, S.E. Mason, C.V. White and M.A. Shuwall, 1991, The use of antidepressants for negative symptoms in a subset of schizophrenic patients, Psychopharmacol. Bull. 27, 331.
34. Tennant Jr., F.S., R.A. Rawson and M. Mccann, 1981, Withdrawal from chronic phencyclidine (PCP) dependence with desipramine, Am. J. Psychiatry 138, 845.
35. Troisi, A., A. Pasini, G. Berasni, M. DiMauro and N. Ciani, 1991, Negative symptoms and visual behavior in DSM-III-R prognostic subtypes of schizophreniform disorder, Acta Psychiatr. Scand. 83, 391.
36. Volkow, N.D. and J.S. Fowler, 1992, Neuropsychiatrie disorders: investigation of schizophrenia and substance abuse, Semin. Nucl. Med. 22, 254.